Research articlePublished 2013
Baltic Post-marketing Study of Pegilated Interferon andalpha;-2a 40 KD Efficacy and Safety in Patients with HBeAgandndash;Positive and HBeAgandndash; Negative Chronic Hepatitis B
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Pegilated interferon alpha-2a 40KD (Pegasys?) is registered in European Union, and is indicated for the treatment of HBeAg positive or HBeAg negative chronic hepatitis B in adult patients with compensated liver disease, evidence of viral replication and increased ALT. The aim of this study was to evaluate efficacy and safety of Pegasys? for Pegasys?
Subjects
Infectious DiseasesMicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalVirology & Mycology
- SubjectInfectious Diseases
- SubjectMicrobiology
- BylineArticles whose byline prints “Ludmila Viksna”
- BylineArticles whose byline prints “Agita Jeruma”
- BylineArticles whose byline prints “Gunta Sture”
- BylineArticles whose byline prints “Baiba Rozentale”
- BylineArticles whose byline prints “Andrejs Ivanovs”
- BylineArticles whose byline prints “Jazeps Keiss”
- BylineArticles whose byline prints “Valentina Sondore”
